Huntington DiseaseHT-HDNCT06774443
Hinting Task for Huntington's Disease
An observational study of Huntington Disease, run by University Medical Center Groningen at 1 site in Netherlands.
Trial summary
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, characterized by movement disorders, behavioural disorders and cognitive decline. Especially the behavioural and cognitive symptoms of the disease lead to significant disability and burden for patients as well as caregivers. Read more about this study
- Who is it for?
- Ages 18 to 74 years
- Conditions the study is for
- Huntington Disease
- What is being tested?
- Neuropsychological assessment
- How many people
- 52 participants
- Where
- 1 siteNetherlands
- Study dates
- 1 Sep 2025to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: We aim to include 47 patients with premanifest HD and 20 patients with manifest HD. Patients will be recruited from the Enroll-HD sample of the UMCG and the Huntington outpatient clinic of Noorderbreedte in Grou. All stuParticipants of Enroll-HD that have given consent to be asked to take part in other studies of HD, will be asked to participate in the current study. The study will also be advertised on the website of the Dutch Huntington Society. Participants can sign themselves up via that advertisement. Inclusion and all other study-related activities will be performed by UMCG study staff. Data of healthy controls on the Hinting Task has already been obtained from previous studies, and can be used in accordance with the FAIR data principles. Data of healthy controls that have given permission to use their data in similar studies will be included. Controls will be matched to patients so that sex and age distributions do not significantly differ between groups.
Who may be able to join
- Confirmed diagnosis of Huntington's disease via CAG-repeat length analysis, minimum of 40 repeats
- Between 18 and 74 years of age
- Dutch speaking
Who cannot join
- Presence of serious psychiatric disorders or other neurological comorbidities
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Maraike A. Coenen contact
Netherlands1 site, 1 recruiting
- Recruiting
University Medical Center Groningen
Groningen, Provincie Groningen, 9700RB
Floor Gelmers, +31 50 361 46 64, f.gelmers@umcg.nl
Maraike Coenen, m.a.coenen@umcg.nl
About this study
Official title: Sensitivity of the Hinting Task in Patients With Huntington's Disease
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, characterized by movement disorders, behavioural disorders and cognitive decline. Especially the behavioural and cognitive symptoms of the disease lead to significant disability and burden for patients as well as caregivers. One of the cognitive domains affected by HD is social cognition. Social cognition is the ability to perceive, interpret and respond correctly to social information. Aspects of social cognition are emotion recognition, perspective taking (Theory of Mind), and emapathy. Social cognition problems can be related to behavioural problems, but to be able to study this relationship, it is important to be able to reliable measure social cognition impairments. There are a few social cognition tests available, but often they are not normd and validated for use in a Dutch neurological population. There is a lack of sensitive, simple, tests for measuring Theory of Mind in patients with HD. A promising test, that already has been proven valid in a psychiatric population, is the Hinting Task. The Hinting Task measures theory of mind through indirect speech, The Hinting task is a social cognition test, where hints are implicitly given in speech, which resembles what patients and caregivers frequently report as difficult in HD. The Hinting Task has already been translated into Dutch and is already being used in clinical parctice, but its sensitivity has not been studied yet in a neurological population. The aim of this study is to assess if the Hinting Task is sensitive in patients with HD and to relate the Hinting Task to other (social) cognitive measures, demographical characteristics and disease characteristics.
- Conditions
- Huntington Disease
- Being tested
- Neuropsychological assessment
- Keywords
- Social Cognition, Theory of Mind, Hinting Task, Huntington, CAG repeat
- Medical subject headings
- Huntington Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuropsychological assessmentOther
Neuropsychological assessment consisting of tests measuring social cognition and memory
| Study group | Role | What they receive |
|---|---|---|
| Patients with HD | Will undergo a neuropsychological assessment Receives: Other: Neuropsychological assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Performance on the Hinting Task
Performance on the Hinting Task by patients with Huntington's disease compared to healthy controls
Measured: 2025-2026
Secondary outcomes (1)
Relations of the Hinting Task with other variables
Relationship of the Hinting Task with other (social) cognitive tests, disease characteristics and demographical characteristics
Measured: 2025-2026
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2025
- Study start1 Sep 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Huntington DiseaseStudies of the same condition, open and under way.
- More trials run by University Medical Center GroningenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 52 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Medical Center Groningen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Maraike Coenen, Principal investigator, University Medical Center Groningen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06774443
- Sponsor's protocol ID
- t.b.a
- Acronym
- HT-HD
- Status last verified
- Nov 2025
- First submitted
- 3 Dec 2024
- Last updated
- 29 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Data can be shared upon request.
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sensitivity of the Hinting Task in Patients With Huntington's Disease
- ClinicalTrials.gov ID
- NCT06774443
- Acronym / sponsor ID
- HT-HD / t.b.a
- Conditions
- Huntington Disease
- Keywords
- Social Cognition, Theory of Mind, Hinting Task, Huntington, CAG repeat
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 52 participants (estimated)
- Lead sponsor
- University Medical Center GroningenUniversity, hospital or other
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 14 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, characterized by movement disorders, behavioural disorders and cognitive decline. Especially the behavioural and cognitive symptoms of the disease lead to significant disability and burden for patients as well as caregivers. One of the cognitive domains affected by HD is social cognition. Social cognition is the ability to perceive, interpret and respond correctly to social information. Aspects of social cognition are emotion recognition, perspective taking (Theory of Mind), and emapathy. Social cognition problems can be related to behavioural problems, but to be able to study this relationship, it is important to be able to reliable measure social cognition impairments. There are a few social cognition tests available, but often they are not normd and validated for use in a Dutch neurological population. There is a lack of sensitive, simple, tests for measuring Theory of Mind in patients with HD. A promising test, that already has been proven valid in a psychiatric population, is the Hinting Task. The Hinting Task measures theory of mind through indirect speech, The Hinting task is a social cognition test, where hints are implicitly given in speech, which resembles what patients and caregivers frequently report as difficult in HD. The Hinting Task has already been translated into Dutch and is already being used in clinical parctice, but its sensitivity has not been studied yet in a neurological population. The aim of this study is to assess if the Hinting Task is sensitive in patients with HD and to relate the Hinting Task to other (social) cognitive measures, demographical characteristics and disease characteristics.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with HD | – | Other: Neuropsychological assessmentWill undergo a neuropsychological assessment |
Who may qualify
- Ages
- 18 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- We aim to include 47 patients with premanifest HD and 20 patients with manifest HD. Patients will be recruited from the Enroll-HD sample of the UMCG and the Huntington outpatient clinic of Noorderbreedte in Grou. All stuParticipants of Enroll-HD that have given consent to be asked to take part in other studies of HD, will be asked to participate in the current study. The study will also be advertised on the website of the Dutch Huntington Society. Participants can sign themselves up via that advertisement. Inclusion and all other study-related activities will be performed by UMCG study staff. Data of healthy controls on the Hinting Task has already been obtained from previous studies, and can be used in accordance with the FAIR data principles. Data of healthy controls that have given permission to use their data in similar studies will be included. Controls will be matched to patients so that sex and age distributions do not significantly differ between groups.
Key inclusion criteria (3 listed)
- Confirmed diagnosis of Huntington's disease via CAG-repeat length analysis, minimum of 40 repeats
- Between 18 and 74 years of age
- Dutch speaking
Key exclusion criteria (1 listed)
- Presence of serious psychiatric disorders or other neurological comorbidities
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuropsychological assessmentNeuropsychological assessment consisting of tests measuring social cognition and memory | Other | Patients with HD |
Primary outcome
Performance on the Hinting Task
Time frame: 2025-2026
Performance on the Hinting Task by patients with Huntington's disease compared to healthy controls
1 secondary outcome
Relations of the Hinting Task with other variables
Time frame: 2025-2026
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2026.
- Individual participant dataSharing planned: Undecided. Data can be shared upon request.
Related trials for Huntington Disease
RecruitingPhase 2/3
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Huntington Disease
Not yet recruiting
Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's Disease
Huntington Disease, Sarcopenia
RecruitingPhase 3
Pridopidine Phase 3 Study in Huntington's Disease
Huntington Disease
Recruiting
Feasibility and Acceptability of an LLM-based Chatbot for Family Caregivers: Evaluation Study
Caregivers
RecruitingObservational study
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Maraike A. Coenen contact
Maraike Coenen principal investigator
University Medical Center Groningen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Huntington Disease, run by University Medical Center Groningen at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Floor Gelmers (+31 50 361 46 64, f.gelmers@umcg.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Performance on the Hinting Task (time frame: 2025-2026). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2026.